Hsa_circ_0001073 targets <scp>miR</scp>‐626/<scp>LIFR</scp> axis to inhibit lung cancer progression

Li, Qun; Cao, Gang; Wan, Yufeng; Xu, Chuanqin; He, Yuan-qiang; Li, Gang

doi:10.1002/tox.23104

Cited by 23 publications

(10 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the ligands of LIFR, LIF is overexpressed and has been identified playing a tumor-promoting role in various tumors, including prostate, nasopharyngeal, breast, gastric, endometrial, colorectal, melanoma, osteosarcoma, lung and pancreatic cancers (2)(3)(4)(5)(6)(7)(8)(9)(10). Recently, increasing numbers of studies have been exploring the cancer type-specific role of LIFR in these cancers (11)(12)(13)(14)(15)(16). LIFR is expressed in a variety of organs and cell types and is involved in angiogenesis, cancer progression, development and regulation of stem cells (2,4,10,17).…”

Section: Introductionmentioning

confidence: 99%

Pan-cancer analysis identifies LIFR as a prognostic and immunological biomarker for uterine corpus endometrial carcinoma

Zhang

Wang²,

Li³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

BackgroundLeukemia inhibitory factor (LIF) exhibits significant tumor-promoting function, while its cognate receptor (LIFR) is considered to act as either a tumor promoter or suppressor. Dysregulation of LIF and LIFR is associated with the initiation, progression and metastasis of multiple cancer entities. Although increasing numbers of studies are revealing an indispensable critical role of LIFR in tumorigenesis for various different cancers, no systematic analysis of LIFR has appeared thus far.MethodsHere, we comprehensively analyzed the expression profile and prognostic value of LIFR, and correlations between LIFR and the infiltration of immune cells and clinicopathological parameters across different tumor types using several bioinformatic tools. The expression profile of LIFR in various tumor types and clinical stages was investigated using the TIMER2 and GEPIA2 databases. Genetic alternations of LIFR were extracted from cBioPortal. The prognostic value of LIFR was assessed using GEPIA2 and Sanger box databases, and correlations between LIFR expression and immune infiltration were analyzed using the CIBERSORT method and TIMER2 database. The correlations between LIFR expression and immune and stromal scores were assessed using ESTIMATE. We also analyzed correlations between LIFR and immunoregulators. Finally, we detected an effect of LIFR on Uterine Corpus Endometrial Carcinoma (UCEC) and evaluated the expression level of LIFR in clinical UCEC samples.ResultsAberrant expression of LIFR in cancers and its prognosis ability, especially in UCEC was documented. Significantly lower levels of LIFR expression level correlated with better prognosis in multiple tumor types. LIFR expression was positively correlated with the abundance of cancer-associated fibroblasts (CAFs) and endothelial cells in the tumor microenvironment. Additionally, LIFR expression was strongly associated with the presence of immune modulators and checkpoint genes. Overexpression of LIFR suppressed the migration and invasion of UCEC cells in vitro.ConclusionOur pan-cancer detection data provided a novel understanding of the roles of LIFR in oncogenesis.

show abstract

Section: Introductionmentioning

confidence: 99%

Pan-cancer analysis identifies LIFR as a prognostic and immunological biomarker for uterine corpus endometrial carcinoma

Zhang

Wang²,

Li³

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…For example, in AML, hsa_circ_0001947 can inhibit disease progression by regulating the hsa-miR-329-5p/CREBRF axis, 15 while circ_0006404 enhances the progression of prostate cancer progression via the miR-1299/CFL2 axis, 16 and hsa_circ_0001073 can suppress the progression of lung cancer via modulating miR-626/LIFR axis signaling. 17 In previous studies, hsa_circ_0079480, which is encoded on chr7:16298014-16317851, has been identified as an oncogenic driver of AML capable of promoting tumor progression through the miR-654-3p/HDGF regulatory axis. 18 The clinical importance of serum hsa_circ_0079480 in AML patients, however, has yet to be established, and this study was therefore designed to examine the prognostic value of hsa_circ_0079480 levels in the serum of individuals with AML.…”

Section: Introductionmentioning

confidence: 99%

“…Mechanistically, circRNAs can bind to specific microRNAs (miRNAs) in a sequence‐specific manner, thereby serving as competing endogenous RNAs (ceRNAs) to prevent miRNA‐mediated repression of mRNA expression. For example, in AML, hsa_circ_0001947 can inhibit disease progression by regulating the hsa‐miR‐329‐5p/CREBRF axis, 15 while circ_0006404 enhances the progression of prostate cancer progression via the miR‐1299/CFL2 axis, 16 and hsa_circ_0001073 can suppress the progression of lung cancer via modulating miR‐626/LIFR axis signaling 17 …”

Section: Introductionmentioning

confidence: 99%

“…For example, in AML, hsa_circ_0001947 can inhibit disease progression by regulating the hsa‐miR‐329‐5p/CREBRF axis, 15 while circ_0006404 enhances the progression of prostate cancer progression via the miR‐1299/CFL2 axis, 16 and hsa_circ_0001073 can suppress the progression of lung cancer via modulating miR‐626/LIFR axis signaling. 17 …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Serum hsa_circ_0079480 is a novel prognostic marker for acute myeloid leukemia

Guo

Kou

Song

et al. 2022

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background The dysregulated expression of serum circular RNAs (circRNAs) has previously been linked to the prognosis of acute myeloid leukemia (AML) patients, but the clinical and prognostic relevance of serum hsa_circ_0079480 levels in this oncogenic setting have yet to be established. Herein, we assessed the putative prognostic relevance of circulating hsa_circ_0079480 levels in AML patient serum. Methods Serum was prepared from blood samples collected from 236 AML patients and 160 healthy controls, with hsa_circ_0079480 levels therein being quantified by quantitative real‐time reverse transcription‐polymerase chain reaction (qRT‐PCR) after which the clinical value of these levels was assessed. Results Acute myeloid leukemia patients were found to exhibit significant hsa_circ_0079480 upregulation in their serum as compared to serum from healthy controls, with such upregulation being most profound in individuals with M4/M5 type disease and to be more common in patients with poor cytogenic risk or high white blood cell counts. Receiver operating characteristic (ROC) curves demonstrated that serum hsa_circ_0079480 levels were able to effectively differentiate between patients with AML and healthy controls. Moreover, the upregulation of serum hsa_circ_0079480 was found to be closely related to clinicopathological findings and to be an independent predictor of reduced overall and relapse‐free survival among individuals diagnosed with AML. Furthermore, serum hsa_circ_0079480 levels were markedly decreased after treatment in this patient population, with these levels being lower in patients that achieved complete remission as compared to those patients that did not. Conclusion Levels of hsa_circ_0079480 in patient serum may offer value as a prognostic biomarker in AML.

show abstract

“…CircRNAs are available to perform as a sponge of microRNAs (miRNAs) and indirectly modulate downstream genes, thus mediating the metastasis and other biological functions of cancer cells [ 9 , 10 ]. For instance, circ_0001073 is reported to repress LC advancement via miR-626/LIFR axis, clarifying the latent value of circ_0001073 in LC therapy [ 11 ]. Meanwhile, a study proposes that circ-CCS is elevated in LC and forecasts unpleasing prognosis [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Circular RNA UBR1 promotes the proliferation, migration, and invasion but represses apoptosis of lung cancer cells via modulating microRNA-545-5p/SSFA2 axis

Mao

Zhang

et al. 2021

Bioengineered

View full text Add to dashboard Cite

Lung cancer (LC) is a malignant tumor with the highest incidence in the world, and its specific pathogenesis is still unclear. Circular RNAs (circRNAs) are a group of non-coding RNAs that play a key role in the development and progression of various cancers. The expression pattern and function of circRNAs in LC are still not completely distinct. In this study, it was aimed to study the expression and potential mechanism of circ-UBR1 in LC cells. Then it was found that circ-UBR1 was up-regulated in LC cells, and had microRNA (miR)-545-5p binding sites. Meanwhile, it was confirmed by dual-luciferase reporter assay that circ-UBR1 directly bound to miR-545-5p and then repressed its expression. MiR-545-5p was down-regulated in LC cells and refrained its expression by binding to the downstream target gene SSFA2. Knockdown circ-UBR1 or enhancive miR-545-5p repressed A549 cell proliferation, migration, and invasion, but accelerated apoptosis. After transfection with circ-UBR1 low expression vector, upregulation of SSFA2 apparently reversed the depression of reduced circ-UBR1 on cell proliferation, migration, and invasion, and the promotion of cell apoptosis. Further tumor xenograft experiments in nude mice also confirmed that knockdown of circ-UBR1 could increase the expression of miR-545-5p, but decrease the expression of SSFA2, thus alleviating the progression of LC in vivo . Therefore, these results fully indicate that circ-UBR1 promotes LC cell proliferation, migration, and invasion, but represses apoptosis via the circ-UBR1 axis, which may be a closely related marker and therapeutic target of LC.

show abstract

Hsa_circ_0001073 targets miR‐626/LIFR axis to inhibit lung cancer progression

Cited by 23 publications

References 38 publications

Pan-cancer analysis identifies LIFR as a prognostic and immunological biomarker for uterine corpus endometrial carcinoma

Pan-cancer analysis identifies LIFR as a prognostic and immunological biomarker for uterine corpus endometrial carcinoma

Serum hsa_circ_0079480 is a novel prognostic marker for acute myeloid leukemia

Circular RNA UBR1 promotes the proliferation, migration, and invasion but represses apoptosis of lung cancer cells via modulating microRNA-545-5p/SSFA2 axis

Contact Info

Product

Resources

About